Montelukast, a leukotriene receptor antagonist, in vernal keratoconjunctivitis associated with asthma.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  A M A Archives of Ophthalmology

• Publication date

  2003-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/ARCHOPHT.121.5.615PMID 12742837
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Levels of prostaglandin E2 and leukotriene B4 in tears of vernal conjunctivitis patients during a therapeutic trial with indomethacin

  2005influential reference
• Leukotriene receptor antagonists for the treatment of allergic rhinitis

  2002cited by this paper
• Montelukast in the Treatment of Children with Moderate-To-Severe Atopic Dermatitis: A Pilot Study

  2002cited by this paper
• Efficacy of leukotriene receptor antagonist in chronic urticaria. A double‐blind, placebo‐controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid

  2001cited by this paper
• An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma

  2001cited by this paper
• Emerging role of antileukotriene therapy in allergic rhinitis

  2001cited by this paper
• Montelukast in the treatment of children with moderate‐to‐severe atopic dermatitis:
A pilot study

  2001cited by this paper
• Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup.

  2000influential reference
• Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma.

  1999cited by this paper
• Treatment of asthma with drugs modifying the leukotriene pathway.

  1999cited by this paper
• Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction.

  1998cited by this paper
• Effects of lodoxamide, disodium cromoglycate and fluorometholone on tear leukotriene levels in vernal keratoconjunctivitis

  1998influential reference
• Pathogenesis of allergic rhinitis.

  1997cited by this paper
• Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma.

  1996cited by this paper
• Vernal keratoconjunctivitis: a model of 5q cytokine gene cluster disease.

  1995cited by this paper
• Persistent increase in plasma and urinary leukotrienes after acute asthma.

  1995cited by this paper
• Effect of extended wear disposable contact lenses on tear LTC4 in giant papillary conjunctivitis.

  1995influential reference
• IgE and non-IgE mechanisms in ocular allergy.

  1993influential reference
• Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy.

  1993cited by this paper
• The Eosinophil Has a Pivotal Role in Allergic Inflammation of the Eye.

  1992cited by this paper
• Allergic and immunologic disorders of the eye.

  1992cited by this paper
• Rhinology Abstracts

  1991cited by this paper
• Inflammatory mediator release on conjunctival provocation of allergic subjects with allergen.

  1990influential reference
• The role of arachidonate metabolites in ocular inflammation.

  1989cited by this paper
• Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases.

  1989cited by this paper
• Vernal keratoconjunctivitis.

  1988cited by this paper
• Characterization of the conjunctival vasopermeability response to leukotrienes and their involvement in immediate hypersensitivity.

  1988cited by this paper
• Behavior and clinical relevance of histamine and leukotrienes C4 and B4 in grass pollen-induced rhinitis.

  1987cited by this paper
• Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans

  1986cited by this paper
• Leukotrienes cause eosinophil emigration into conjunctival tissue.

  1986cited by this paper
• Production of Leukotrienes in Human Skin and Conjunctival Mucosa after Specific Allergen Challenge

  1985cited by this paper
• Effect of LTD4 on conjunctival vasopermeability and blood-aqueous barrier integrity.

  1985cited by this paper
• Ocular Allergy

  1985cited by this paper
• In vivo metabolism of leukotriene C4 in man: urinary excretion of leukotriene E4.

  1985cited by this paper
• Peptide leukotriene release after antigen challenge in patients sensitive to ragweed.

  1984cited by this paper
• Detection of leukotriene C4-liked immunoreactivity in tear fluid from subjects challenged with specific allergen.

  1984cited by this paper
• Synthesis of slow reacting substance-like activity in rabbit conjunctiva and anterior uvea.

  1983cited by this paper
• Effects of arachidonic acid, monohydroxyeicosatetraenoic acid and prostaglandins on the release of mucous glycoproteins from human airways in vitro.

  1981cited by this paper
• Immunological investigations in vernal eye disease.

  1980cited by this paper
• Ocular allergy.

  1962cited by this paper

• New insights on pharmacological potential of montelukast: a comprehensive review

  2025cites this paper
• A review on pathophysiology and managements of allergic conjunctivitis

  2024cites this paper
• Novel Insights in the Management of Vernal Keratoconjunctivitis (VKC): European Expert Consensus Using a Modified Nominal Group Technique

  2023cites this paper
• Management of vernal keratoconjunctivitis: Navigating a changing treatment landscape.

  2023cites this paper
• Efficacy of medical treatments for vernal keratoconjunctivitis: a systematic review and meta-analysis.

  2021cites this paper
• Montelukast microsuspension with hypromellose for improved stability and oral absorption.

  2021cites this paper
• Efficacy of montelukast in preventing seasonal recurrence of vernal keratoconjunctivitis in children

  2021influential citation
• Montelukast Nanocrystals for Transdermal Delivery with Improved Chemical Stability

  2019cites this paper
• Pathophysiology of Allergic Rhinitis

  2019cites this paper
• The Role of Leukotrienes as Potential Therapeutic Targets in Allergic Disorders

  2019cites this paper
• Evaluation of IL8 pathway on the ocular surface: new insights in patients with ocular mucous membrane pemphigoid

  2019cites this paper
• Management of Ocular Surface Allergic Diseases

  2018cites this paper
• Study of Clinical Features and Management of Vernal Keratoconjunctivitis

  2017cites this paper
• Current and emerging treatment options for vernal keratoconjunctivitis

  2017cites this paper
• The role of leukotrienes in allergic diseases.

  2015cites this paper
• Phase II drugs under investigation for allergic conjunctivitis

  2014cites this paper
• Hen’s egg white hypersensitivity among a group of Egyptian atopic children

  2014cites this paper
• Leukotrienes and leukotriene modifiers in pediatric allergic diseases

  2014cites this paper
• 14 – Vernal Keratoconjunctivitis

  2013cites this paper
• Anti-Leukotrienes in the treatment of allergic conjunctivitis and comorbidities in children: An update

  2013cites this paper
• A Practical Approach to Management of Allergic Eye Conditions in Children

  2013cites this paper
• Leukotriene receptor antagonists in allergic eye disease: a systematic review and meta-analysis.

  2013cites this paper
• Emerging therapies in allergic conjunctivitis and dry eye syndrome

  2013cites this paper
• Montelukast as a New Topical Ocular Therapeutic Agent for Treatment of Allergic Conjunctivitis : an Experimental Comparative Study

  2012cites this paper
• Vernal keratoconjunctivitis: an update

  2012cites this paper
• Leukotriene Antagonist Drugs as Treatment of Allergic Conjunctivitis and Comorbidities in Children

  2011influential citation
• Mediators and Some Cytokines in Tears During the Late Conjunctival Response Induced by Primary Allergic Reaction in the Nasal Mucosa

  2011cites this paper
• Conjunctival Goblet Cell Secretion Stimulated by Leukotrienes Is Reduced by Resolvins D1 and E1 To Promote Resolution of Inflammation

  2011cites this paper
• of Inflammation Resolvins D1 and E1 To Promote Resolution Stimulated by Leukotrienes Is Reduced by Conjunctival Goblet Cell Secretion

  2011cites this paper
• Allergie et surface oculaire chez le sujet âgé

  2010cites this paper
• Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision.

  2010cites this paper
• Therapeutische Optionen bei Keratoconjunctivitis vernalis

  2009cites this paper
• Allergic Conjunctivitis: Update on Its Pathophysiology and Perspectives for Future Treatment

  2009cites this paper
• Vernal keratoconjunctivitis: a major review

  2009cites this paper
• Managing a child with an external ocular disease.

  2009cites this paper
• Ocular Allergy: Clinical, Therapeutic and Drug Discovery Considerations

  2008cites this paper
• Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 *

  2008cites this paper
• Allergic conjunctivitis: presentation, diagnosis, and management

  2008influential citation
• Antileukotriene drugs: clinical application, effectiveness and safety.

  2007cites this paper
• Montelukast in pediatric asthma management

  2006cites this paper
• [Ocular allergies].

  2005cites this paper
• Emerging drugs for ocular allergy

  2005cites this paper
• Brief Review: Advances in Therapy with Antileukotriene Drugs

  2004cites this paper
• Ocular allergic disease

  2004cites this paper
• Advances in therapy with antileukotriene drugs.

  2004cites this paper
• Vernal keratoconjunctivitis

  2004cites this paper
• Allergic chronic inflammation of the ocular surface in vernal keratoconjunctivitis

  2003cites this paper
• Genetics of asthma: current research paving the way for development of personalized drugs.

  2003cites this paper
• Vernal conjunctivitis.

  1997cites this paper